All In Biotech

Drug Trial Radar · NCT07758660

Alzheimer's Disease Research Center (ADRC) PET Component Study

Alzheimer's Disease Research Center PET Component

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

120

Planned (sponsor's estimate)

Start

Aug 6, 2026

Primary completion

May 31, 2031

Study completion May 31, 2033

Sponsor

Lead sponsor
Patrick LaoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Aging (NIA)
First posted
Aug 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to further engage and characterize Alzheimer's Disease Research Center (ADRC) participants through additional research opportunities, particularly PET imaging. Amyloid and Tau PET imaging will be collected in 24 participants per year, for a total of 120 participants over five years. All participants will be followed longitudinally, including through potential transitions from normal aging to mild cognitive impairment (MCI) and Alzheimer's disease and related dementias (ADRD).

Conditions

  • Alzheimer Disease
  • Mild Cognitive Impairment (MCI)
  • Dementia

Interventions

  • 18F-MK6240Drug

    MK-6240 is experimental but has been used in several human studies before and has been proven to accurately measure tau in the brain.

  • 18F-Florbetaben (FBB)Drug

    Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. Florbetaben measures amyloid in the brain.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 18F-FBB Standardized Uptake Value RatioTime frame: Up to 12 months
  2. 18F-MK6240 Standardized Uptake Value RatioTime frame: Up to 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Columbia University Irving Medical Center

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.